# Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease

> **NCT02074410** · PHASE2 · TERMINATED · sponsor: **Omeros Corporation** · enrollment: 22 (actual)

## Conditions studied

- Huntington's Disease

## Interventions

- **DRUG:** OMS643762
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02074410
- **Lead sponsor:** Omeros Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01
- **Primary completion:** 2014-10-15
- **Final completion:** 2014-10-15
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Sponsor decision - pending further analysis of available data
- **Last updated:** 2018-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02074410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02074410, "Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02074410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*